Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Scientists at GE Healthcare detail research in breast cancer
June 18th, 2009
According to recent research published in the journal Nuclear Medicine and Biology, "Molecular targeting has become a prominent concept in cancer treatment and heat shock protein 90 (Hsp%) inhibitors are suggested as promising anticancer drugs. The Hsp90 complex is one of the chaperones that facilitate the refolding of unfolded or misfolded proteins and plays a role for key oncogenic proteins Such as Her2, Raf-1, Akt/PKB, and mutant p53." "NVP-AUY922 is a novel low-molecular Hsp90 inhibitor, currently under clinical development as an anticancer drug. Disruption of the Hsp90-client protein complexes leads to proteasome-mediated degradation of client proteins and...
Source: Women's Health Weekly (2009-06-18)
|
